3,491,620 Shares Liquidia Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • December 14th, 2023 • Liquidia Corp • Pharmaceutical preparations • New York
Contract Type FiledDecember 14th, 2023 Company Industry JurisdictionIntroductory. Liquidia Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) an aggregate of 3,491,620 shares of its common stock, par value $0.001 per share (the “Shares”). The 3,491,620 Shares to be sold by the Company are called the “Offered Shares.” BofA Securities, Inc. (“BofA”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”) in connection with the offering and sale of the Offered Shares. To the extent there are no additional underwriters listed on Schedule A, the term “Representative” as used herein shall mean you, as Underwriter, and the term “Underwriters” shall mean either the singular or the plural, as the context requires.
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • December 14th, 2023 • Liquidia Corp • Pharmaceutical preparations • New York
Contract Type FiledDecember 14th, 2023 Company Industry JurisdictionCOMMON STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of December 12, 2023, by and among Liquidia Corporation, a Delaware corporation, with headquarters located at 419 Davis Drive, Suite 100, Morrisville, NC 27560 (the “Company”) and each of the investors listed on the Schedule of Buyers attached hereto (individually, a “Buyer” and collectively, the “Buyers”).